Abstract |
Background Dual inhibition of activated MAPK and mTOR signaling pathways may enhance the antitumor efficacy of the MEK 1/2 inhibitor pimasertib and the mTOR inhibitor temsirolimus given in combination. Methods In this phase I study, patients with refractory advanced solid tumors (NCT01378377) received once-weekly temsirolimus plus once-daily oral pimasertib in 21-day cycles in a modified 3 + 3 dose-escalation design. The maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of pimasertib in combination with temsirolimus, safety and pharmacokinetics (PK) were investigated. Results Of 33 patients evaluated, all experienced ≥1 treatment-emergent adverse event (TEAE) and 31 had treatment-related TEAEs, most frequently stomatitis and thrombocytopenia. TEAEs were reversible. No deaths were attributed to treatment. Nine patients had dose-limiting toxicities ( stomatitis, thrombocytopenia, serum creatinine phosphokinase increase, visual impairment) and the MTD was determined as 45 mg/day pimasertib plus 25 mg/week temsirolimus. However, due to overlapping toxicities no further investigations were performed and the RP2D was not defined. PK profiles of both agents were not adversely affected. Seventeen patients (17/26 patients) had a best response of stable disease; five had stable disease lasting >12 weeks. Conclusions The RP2D was not defined and the pimasertib plus temsirolimus combination investigated did not warrant further study.
|
Authors | Monica Mita, Siqing Fu, Sarina Anne Piha-Paul, Filip Janku, Alain Mita, Ronald Natale, Wei Guo, Charles Zhao, Razelle Kurzrock, Aung Naing |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 35
Issue 5
Pg. 616-626
(10 2017)
ISSN: 1573-0646 [Electronic] United States |
PMID | 28194539
(Publication Type: Clinical Trial, Phase I, Journal Article)
|
Chemical References |
- N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
- Protein Kinase Inhibitors
- Niacinamide
- temsirolimus
- MTOR protein, human
- TOR Serine-Threonine Kinases
- MAP Kinase Kinase Kinase 1
- MAP Kinase Kinase Kinase 2
- Sirolimus
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Female
- Humans
- MAP Kinase Kinase Kinase 1
(antagonists & inhibitors)
- MAP Kinase Kinase Kinase 2
(antagonists & inhibitors)
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasms
(drug therapy, metabolism)
- Niacinamide
(administration & dosage, analogs & derivatives)
- Protein Kinase Inhibitors
(administration & dosage)
- Sirolimus
(administration & dosage, analogs & derivatives)
- TOR Serine-Threonine Kinases
(antagonists & inhibitors)
- Young Adult
|